Boehringer ingelheim

Index
Globenewswire

JASCAYD® (nerandomilast) Receives First Regulatory Approval for Progressive Pulmonary Fibrosis in China

Globenewswire

Boehringer Ingelheim announces appointment to Board of Managing Directors

Globenewswire

Boehringer Ingelheim Obtains two EU CVMP Positive Opinions for Avian Influenza Vaccines VAXXITEK® HVT+IBD+H5 and VAXXINACT® H5

Globenewswire

Boehringer Ingelheim and CDR-Life Expand Collaboration Efforts with Global Licensing Agreement for CDR111, an Antibody-Based Trispecific M-gager® for Autoimmune Diseases

Globenewswire

Boehringer Ingelheim Acquires License from Kyowa Kirin Aimed at Developing a Novel Treatment for Patients with Autoimmune Diseases

Globenewswire

JASCAYD® (nerandomilast) Approved in China for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Globenewswire

Boehringer’s Zongertinib Demonstrated a 77% Objective Response Rate in Treatment-naïve Patients with Advanced HER2 (ERBB2)-mutant NSCLC

Globenewswire

Boehringer Ingelheim Advances Cancer Antibody-drug Conjugate Portfolio with Asset from AimedBio

Globenewswire

U.S. FDA Approves Boehringer’s JASCAYD® (nerandomilast tablets) as First New Treatment Option for Adults with IPF in Over a Decade

Globenewswire

Pooled Data Presented at ERS: Nerandomilast Monotherapy Linked to Nominally Significant Reduction in Risk of Death in IPF and PPF

Globenewswire

Boehringer’s HERNEXEOS® Approved in China as First Oral Targeted Therapy for Previously Treated Patients with HER2-mutant Advanced NSCLC

Globenewswire

Boehringer Ingelheim and Palatin Technologies to Develop Potential First-in-class Melanocortin Receptor Targeted Treatment for Patients with Retinal Diseases

Globenewswire

Boehringer and Click Therapeutics’ Investigational Prescription Digital Therapeutic CT-155 Meets Primary Endpoint in CONVOKE Study for Negative Symptoms in Schizophrenia

Globenewswire

Boehringer Ingelheim and Re-Vana Therapeutics Announce Strategic Collaboration to Develop Long-Acting Ophthalmic Therapies

Globenewswire

First Half of 2025: Solid Growth, Investments and Pipeline Progress Pave the Way for Two Key Launches in H2

Globenewswire

Boehringer Ingelheim Initiates Phase II Study of BI 1815368, a Potential First-in-class Oral Treatment for Diabetic Macular Edema

Globenewswire

Boehringer Ingelheim and Eko Health Inc. Enter Digital Health Collaboration to Improve Heart Murmur Detection in Dogs

Globenewswire

Boehringer Ingelheim to Present Early Clinical Evidence of Innate Immune Modulation and Anti-tumor Activity Via SIRPα Blockade in Two Ongoing Trials at ASCO 2025

Globenewswire

Global Phase III Trials Demonstrate That Nerandomilast Slowed Lung Function Decline in IPF and PPF, with Similar Discontinuation Rates to Placebo

Globenewswire

Boehringer Ingelheim Starts Phase II Study of its Potential First-in-class Oral Compound as a Treatment for Geographic Atropy

Globenewswire

Breaking New Ground in Mental Health Research: Oxford University, Boehringer Ingelheim, and Cumulus Neuroscience Launch First of its Kind Study Investigating the Day-to-day Experience of Patients with Psychiatric Disorders

Globenewswire

Boehringer’s New Zongertinib Data Demonstrate Durable and Clinically Meaningful Results in Patients with HER2 (ERBB2)-mutant Advanced NSCLC

Globenewswire

New Survey Shows that Over 90% of Animal Owners Trust and Appreciate Veterinary Teams but Underestimate the Demands of the Profession

Globenewswire

Boehringer Ingelheim and Tessellate Bio Partner to Develop First-in-class Precision Treatments for People with Hard-to-treat Cancers

Globenewswire

Boehringer Ingelheim Announces Succession Chairmen Shareholders’ Committee and Board of Managing Directors